IOPROMIDE


Trade Names	ULTRAVIST (PHARMACY BULK) ULTRAVIST 150 ULTRAVIST 240 ULTRAVIST 300 ULTRAVIST 300 IN PLASTIC CONTAINER ULTRAVIST 370
Synonyms	Iopromide Proscope Ultravist Ultravist (pharmacy bulk) Ultravist 150 Ultravist 240 Ultravist 300 Ultravist 370 ZK 35760 ZK-35760
Status
Molecule Category	Free-form
ATC	V08AB05
UNII	712BAC33MZ
EPA CompTox	DTXSID0023163


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	DGAIEPBNLOQYER-UHFFFAOYSA-N
Smiles	COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I
InChI	InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H24I3N3O8
Molecular Weight	791.11
AlogP	-0.41
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	6.0
Number of Rotational Bond	11.0
Polar Surface Area	168.66
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	32.0

Bioactivity

Mechanism of Action	Action	Reference
Diagnostic agent	None	DailyMed

Related Entries

Environmental Exposure

Environmental Exposure Map

Countries
Croatia
Hungary
Romania
Slovakia
Slovenia

Cross References

Resources	Reference
ChEBI	63578
ChEMBL	CHEMBL1725
DrugBank	DB09156
DrugCentral	1468
FDA SRS	712BAC33MZ
Human Metabolome Database	HMDB0041910
PubChem	3736
SureChEMBL	SCHEMBL24546

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).